HC Wainwright & Co. Reiterates Buy on Protara Therapeutics, Maintains $23 Price Target

HC Wainwright & Co. analyst Andrew Fein reiterates Protara Therapeutics (NASDAQ:TARA) with a Buy and maintains $23 price target.

HC Wainwright & Co. analyst Andrew Fein reiterates Protara Therapeutics (NASDAQ:TARA) with a Buy and maintains $23 price target.

Total
0
Shares
Related Posts